Literature DB >> 3432554

Altered prostanoid formation in human umbilical vasculature in response to variations in oxygen tension.

K Bjøro1, G Haugen, S Stray-Pedersen.   

Abstract

Prostanoid formation in human umbilical vessels perfused in vitro was assessed at different oxygen tensions. At an atmosphere of 5% oxygen the production rate of prostacyclin (measured as 6-keto-PGF1 alpha) was higher, while those of thromboxane A2 (measured as TXB2), PGE2 and PGF2 alpha were lower than with 20%, 50% and 95% oxygen. The stimulatory effect of angiotensin II on prostanoid production was found to be independent on the prevailing oxygen tension. Vascular formation of prostanoids thus seems to be at least partially affected by the ambient oxygen tension. Though altered oxygen tension does not seem to affect angiotensin induced prostanoid formation, the action of other vasoactive agents influencing vascular formation of prostanoids may respond differently to hypoxia or hyperoxia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3432554     DOI: 10.1016/0090-6980(87)90083-9

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  4 in total

1.  Nitric oxide and sodium nitroprusside-induced relaxation of the human umbilical artery.

Authors:  F Lovren; C Triggle
Journal:  Br J Pharmacol       Date:  2000-10       Impact factor: 8.739

2.  Characterization and actions of human umbilical endothelium derived relaxing factor.

Authors:  G Chaudhuri; G M Buga; M E Gold; K S Wood; L J Ignarro
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

3.  Abnormalities in the biosynthesis of thromboxane A2 and prostacyclin in children with cyanotic congenital heart disease.

Authors:  I Adatia; S E Barrow; P Stratton; J M Ritter; S G Haworth
Journal:  Br Heart J       Date:  1993-02

4.  Prostacyclin release and receptor activation: differential control of human pulmonary venous and arterial tone.

Authors:  Xavier Norel; Laurence Walch; Jean-Pierre Gascard; Vincent deMontpreville; Charles Brink
Journal:  Br J Pharmacol       Date:  2004-06-01       Impact factor: 8.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.